Summary Acetohydroxamic acid (AHA), an inhibitor of urease, was used in the treatment of coma and azotemia complicating hepatic failure on six occasions in 5 patients. Under the circumstances of the study, no consistent clinical effect was observed, but a significant reduction in blood am monia concentrations was produced. In dogs with Eck fistulas, AHA reduced fasting blood ammonia concentrations and prevented the hyperammonemia which otherwise occurred after intravenous administration of urea. In animals, the compound is rapidly absorbed from the gastrointestinal tract and excreted in the urine, and no toxic effects were observed. These preliminary data warrant further investigation of the compound as an adjunct to treatment in some instances of hepatic coma.